Molecular structure of A-1210477, CAS Number: 1668553-26-1
A-1210477 (CAS 1668553-26-1)
Alternate Names:
7-[5-[[4-[4-[(dimethylamino)sulfonyl]-1-piperazinyl]phenoxy]methyl]-1,3-dimethyl-1H-pyrazol-4-yl]-1-[2-(4-morpholinyl)ethyl]-3-[3-(1-naphthalenyloxy)propyl]-1H-indole-2-carboxylic acid
CAS Number:
1668553-26-1
Molecular Weight:
850.0
Molecular Formula:
C46H55N7O7S
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
A-1210477 (CAS 1668553-26-1) References
- Albendazole-Induced SIRT3 Upregulation Protects Human Leukemia K562 Cells from the Cytotoxicity of MCL1 Suppression. | Wang, LJ., et al. 2020. Int J Mol Sci. 21: PMID: 32486166
- Anti-Leukemic Properties of Aplysinopsin Derivative EE-84 Alone and Combined to BH3 Mimetic A-1210477. | Song, S., et al. 2021. Mar Drugs. 19: PMID: 34063867
- Mcl-1 Inhibition: Managing Malignancy in Multiple Myeloma. | Al-Odat, O., et al. 2021. Front Pharmacol. 12: 699629. PMID: 34349655
- Hydroquinone destabilizes BIM mRNA through upregulation of p62 in chronic myeloid leukemia cells. | Lee, YC., et al. 2022. Biochem Pharmacol. 199: 115017. PMID: 35346662
- MCL1 Inhibition Overcomes the Aggressiveness Features of Triple-Negative Breast Cancer MDA-MB-231 Cells. | Pratelli, G., et al. 2023. Int J Mol Sci. 24: PMID: 37446326
- Medical Gas Plasma Technology Combines with Antimelanoma Therapies and Promotes Immune-Checkpoint Therapy Responses. | Miebach, L., et al. 2023. Adv Sci (Weinh). 10: e2303183. PMID: 37541287
- Targeting MCL-1 protein to treat cancer: opportunities and challenges. | Tantawy, SI., et al. 2023. Front Oncol. 13: 1226289. PMID: 37601693
- Dihydroartemisinin Enhances the Therapeutic Efficacy of BH3 Mimetic Inhibitor in Acute Lymphoblastic Leukemia Cells via Inhibition of Mcl-1. | Nazmabadi, R., et al. 2024. Asian Pac J Cancer Prev. 25: 325-332. PMID: 38285800
- The Effects of ABT-199 and Dihydroartemisinin Combination on Cell Growth and Apoptosis in Human U937 and KG-1 Cancer Cells. | Nazmabadi, R., et al. 2024. Asian Pac J Cancer Prev. 25: 343-350. PMID: 38285802
- Quantitative systems pharmacology modeling of tumor heterogeneity in response to BH3-mimetics using virtual tumors calibrated with cell viability assays. | Derippe, T., et al. 2024. CPT Pharmacometrics Syst Pharmacol.. PMID: 38747730
Inhibitor of:
Bcl-6b, Bcl-rambo, Bcl-w, BID, FAM136A, FAM136B, HAX-1, Mcl-1, Mcl-1L, MOMP, and PSG9.Activator of:
ATF-5, Bcl-B, FANCI, and Hrk.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
A-1210477, 5 mg | sc-507474 | 5 mg | $195.00 |